youtube_live
Q2 2027 earnings • released • Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥4,410.00
arrow_downward
-1.89%(-85.00) 1D
Nov 20, 1:21:09 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥4,475
High
Â¥4,510
Low
Â¥4,405
Mkt. cap
205.25B
Avg. vol.
109.68K
Volume
81.80K
Dividend
2.83%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.35
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥4,475
High
Â¥4,510
Low
Â¥4,405
Mkt. cap
205.25B
Avg. vol.
109.68K
Volume
81.80K
Dividend
2.83%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.35
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
FOREX.com
·
6 hours ago
S&P 500 Analysis: SPX Is Going Through One of Its Most Difficult Periods of 2026
FXStreet
·
7 hours ago
Dow Jones Industrial Average falls over 1,000 points as Anthropic IPO dominates
Traders Union
·
6 hours ago
S&P 500 sees $2 trillion swing and 8.5 percent drop, Peter Tuchman notes
BigGo Finance
·
4 hours ago
Chip ETF Eyes Unprecedented Fourth Straight Year of Beating the S&P 500
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp